Hippo signalling is a tumour suppressor cascade highly conserved from yeast to man [1] . In mammals, Hippo signalling is deregulated in various cancers; hence, mamma lian Hippo signalling has gained much attention over the past years [2] . In a nutshell, the canonical Hippo pathway functions as follows: activated MST1/2 kinases (mammalian Ste20-like serine/threonine kinase 1/2) phosphorylate hMOB1 (human Mps one binder 1) and LATS1/2 (large tumour suppressor serine/threonine kinase 1/2), resulting in the formation of an active hMOB1-LATS complex that phosphorylates the protooncogenes YAP (Yes-associated protein) and TAZ (transcriptional co-activator with PDZ-binding motif ), which fi nally leads to the accumulation of inactive cytoplasmic YAP/TAZ [3] .
Background
Hippo signalling is a tumour suppressor cascade highly conserved from yeast to man [1] . In mammals, Hippo signalling is deregulated in various cancers; hence, mamma lian Hippo signalling has gained much attention over the past years [2] . In a nutshell, the canonical Hippo pathway functions as follows: activated MST1/2 kinases (mammalian Ste20-like serine/threonine kinase 1/2) phosphorylate hMOB1 (human Mps one binder 1) and LATS1/2 (large tumour suppressor serine/threonine kinase 1/2), resulting in the formation of an active hMOB1-LATS complex that phosphorylates the protooncogenes YAP (Yes-associated protein) and TAZ (transcriptional co-activator with PDZ-binding motif ), which fi nally leads to the accumulation of inactive cytoplasmic YAP/TAZ [3] .
YAP is overexpressed in various human cancers [4, 5] , supporting a role for it as a proto-oncogene. In breast cancer, however, gain or loss of YAP expression has been reported [6] [7] [8] [9] , suggesting that YAP might have oncogenic and tumour suppressive functions dependent on the breast cancer subtype. TAZ is overexpressed in breast cancer [10, 11] , but a recent report [12] suggests also a tumour suppressive role for TAZ. Th erefore, the roles of YAP/TAZ-Hippo signalling in breast cancer are debatable. Considering that metastases at distant sites, and not the primary breast tumour, are the main cause of death, we must further consider YAP/TAZ functions in metastasis, as highlighted by a recent report by Ma and colleagues [13] .
The articles
To uncover novel factors involved in the initiation/ progres sion of tumours, Lippman and colleagues [12] screened in vivo the entire human genome by RNA interference, thereby identifying LIFR as a novel tumour suppressor. Silencing of LIFR was suffi cient to transform normal mammary cells, and reciprocally, LIFR overexpression in breast cancer cells suppressed tumour growth [12] , suggesting that LIFR is a clinically important breast tumour suppressor. However, Iorns and colleagues [12] did not defi ne how LIFR functions as a tumour suppressor.
In parallel, Ma and co-workers discovered a role for LIFR as a novel breast cancer metastasis suppressor [13] . In full agreement with Iorns and colleagues [12] , they also found that LIFR is downregulated in breast cancer [13] , but controversially reported that LIFR silencing did not aff ect primary tumour growth [13] . However, overexpression of LIFR in metastatic breast cancer cell lines dramatically reduced metastases formation [13] . Furthermore, Ma and colleagues investigated the mechanisms downstream of LIFR. Based on a recent report [14] linking LIF (the ligand for LIFR) to the regulation of YAP, they examined the role of LIFR in YAP-Hippo signalling. Unlike in embryonic stem cells [14] , addition of LIF resulted in increased YAP phosphorylation in breast cancer cell lines, thereby resulting in the inactivation of YAP [13] . Since phosphorylation of MST/LATS was
Abstract
The proto-oncogenes YAP and TAZ have previously gained much attention as downstream eff ectors of Hippo tumour suppressor signalling. While the regulation of YAP/TAZ by MST/LATS kinases is reasonably well understood, the nature of factors functioning upstream of MST/LATS is yet to be elucidated in detail. A recent paper by Ma and co-workers defi nes a novel role for leukemia inhibitory factor receptor (LIFR) signalling upstream of the Hippo-YAP pathway in breast cancer metastasis. Moreover, a whole genome in vivo RNA interference screen by Lippmann and colleagues identifi ed LIFR as a breast tumour suppressor. Here, we discuss the implications of these studies for breast cancer research and treatment. increased upon LIFR overexpression [13] , it is possible that the eff ect on YAP is driven by canonical Hippo signalling. Moreover, they provided evidence suggesting that LIFR signals to MST/LATS via Scribble [13] , an adaptor that can link MST/LATS/YAP/TAZ complexes [11] .
The viewpoint
Two recent reports highlight LIFR as a novel player in breast cancer. Th e work by Iorns and colleagues [12] defi nes LIFR as a breast tumour suppressor, while Ma and co-workers [13] defi ne LIFR as a breast cancer metastasis suppressor. Current evidence strongly suggests that LIFR functions by inhibiting YAP [13] . Th is novel role for YAP in breast cancer metastasis is supported by a recent paper from the Hynes laboratory [15] , but the involvement of canonical Hippo signalling is not so evident. Th ey show that LIFR overexpression correlates with increased LATS1 phosphorylation, while YAP(S112A) drives metastases despite LIFR overexpression [13] . Th is suggests that LIFR triggers YAP phosphorylation by activating LATS1. However, given that YAP phosphorylation appears to be independent of LATS1/2 in other cancer settings [16] , it will be important to confi rm the identity of the kinase(s) targeting YAP in these settings before we can make fi nal conclusions.
Considering that TAZ-Hippo signalling is already implicated in breast cancer [10, 11] , it is likely that LIFR also functions upstream of TAZ. In particular, it will be interesting to determine whether the recently reported role for TAZ in breast cancer metastasis [17] is controlled by LIFR. However, Iorns and colleagues identifi ed TAZ (WWTR1) as a potential breast tumour suppressor in their screen [12] . At fi rst glance, these observations do not seem to make sense, but as already speculated for YAP [4, [6] [7] [8] [9] , TAZ might have oncogenic and tumour suppressive functions dependent on the breast cancer subtype or progression stage, a phenomenon already reported for other factors in diff erent cancer types [18] . Since increased YAP/TAZ levels correlate with taxol resistance [7, 19] , YAP/TAZ have been considered as targets/biomarkers in breast cancer. Based on the work by the Ma and Lippman laboratories [12, 13] , however, LIFR activation appears to be the more attractive clinical target for the treatment of breast cancer, since the roles of YAP/TAZ-Hippo signalling in breast cancer subtypes are yet to be defi ned in more detail.
Abbreviations LIF, leukemia inhibitory factor; LIFR, leukemia inhibitory factor receptor.
